In the midst of physician concerns that Part B drug reimbursements are too low, the Department of Health and Human Services’ Office of Inspector General (OIG) is suggesting the Centers for Medicare and Medicaid Services guide drugmakers in calculating the best prices for those drugs.
OIG suggests CMS should help drugmakers calculate Medicare Part B drug prices
